Nbi27914 hydrochloride

LDL was prepared from human plasma by density gradient ultracentrifugation [18 (link)]. Oxidatively modified LDL (oxLDL) was generated by dialysis of LDL with 5 μM CuSO4 in PBS for 6 hours at 37°C. Oxidation was terminated by dialysis against PBS containing EDTA (100 μM). LY294002 was purchased from Enzo (Enzo Life Sciences, NY, USA). NBI27914 hydrochloride was purchased from TOCRIS (Tocris Bioscience, Bristol, U.K.). CRH, oil red O (ORO), 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI), human apolipoprotein A1 (apoA1), and human AB serum were purchased from Sigma (Sigma, St. Louis, MO, USA). The intracellular cholesterol assay kit was purchased from Cayman (Cayman Chemical Co., Ann Arbor, MI, USA). BODIPY-cholesterol was purchased from TopFluor (Avanti Polar Lipids, Inc., Alabaster, AL, USA). Antibodies against ABCA1 and EMR1(F4/80) were purchased from Abcam (Cambridge, MA, USA). Ficoll-paque was purchased from GE (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA)

Imipramine (I0899, Sigma-Aldrich), corticosterone (C2505, Sigma-Aldrich), NBI27914 hydrochloride (1591, Tocris Bioscience), RU486 (M8046, Sigma-Aldrich), and Clozapine N-oxide (CNO) dihydrochloride (6329, Tocris Bioscience) were diluted in 0.9 % saline and injected intraperitoneally in a volume of 120 μl.